Go Deep
Solid Biosciences Inc.
Solid Biosciences Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,595 | -3.1 | 1.67 | 0.05 | 554.26 |
| Oct 2026 | 20,801 | -2.9 | 1.57 | 0.05 | 518.89 |
| Oct 2026 | 20,641 | -3.2 | 1.65 | 0.05 | 545.08 |
| Oct 2026 | 20,763 | -2.9 | 1.58 | 0.05 | 523.77 |
| Oct 2026 | 20,537 | -3.1 | 1.70 | 0.05 | 561.31 |
| Oct 2026 | 20,258 | -3.4 | 1.83 | 0.05 | 606.82 |
| Oct 2026 | 20,252 | -3.4 | 1.84 | 0.05 | 606.27 |
| Oct 2026 | 20,380 | -3.3 | 1.77 | 0.05 | 584.28 |
| Oct 2026 | 20,537 | -3.1 | 1.70 | 0.05 | 561.11 |
Solid Biosciences Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -54,799,000.0 | -56,737,000.0 | -49,787,000.0 | -45,776,000.0 |
| EPS | -0.4 | -0.5 | — | -0.5 |
Solid Biosciences Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 8,094,000.0 | — |
| Net Profit | -174,325,000.0 | -124,697,000.0 | -96,015,000.0 | -85,981,000.0 | — |
| EPS | -2.0 | -3.1 | -4.8 | -10.1 | — |
Solid Biosciences Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 232,540,000.0 | 188,662,000.0 | 164,939,000.0 | 260,252,000.0 | — |
| Total Liabilities | 52,530,000.0 | 51,416,000.0 | 38,458,000.0 | 48,586,000.0 | — |
| Total Equity | 180,010,000.0 | 137,246,000.0 | 126,481,000.0 | 211,666,000.0 | — |
Owes vs Owns
Solid Biosciences Inc. owed $0.11 for every $1 it owned in Jun 2026, down from $0.19 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.11× | 0.23× | 0.27× | 0.23× | 0.19× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Solid Biosciences Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 80.8%Fixed assets (tangible) 11.2%Other assets 8.0%
How it's funded — Dec 2025
Short-term debt 0.9%Long-term debt 8.2%Payables 1.4%Other liabilities 12.1%Shareholders' equity 77.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 187.8 | 148.9 | 123.6 | 213.7 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 26.1 | 29.0 | 33.2 | 38.6 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 18.6 | 10.7 | 8.1 | 7.9 |
| Liabilities & equity | ||||
| Short-term debt | 2.1 | 3.0 | 2.3 | 2.6 |
| Long-term debt | 19.1 | 21.2 | 23.9 | 26.0 |
| Payables | 3.2 | 4.2 | 2.0 | 3.2 |
| Other liabilities | 28.1 | 23.0 | 10.2 | 16.8 |
| Shareholders' equity | 180.0 | 137.2 | 126.5 | 211.7 |
| Net tangible assets | 180.0 | 137.2 | 126.5 | 211.7 |
Solid Biosciences Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -156,289,000.0 | -100,012,000.0 | -94,180,000.0 | -97,977,000.0 | — |
| Investing Activities | -58,454,000.0 | -16,086,000.0 | 9,689,000.0 | 59,157,000.0 | — |
| Financing Activities | 194,446,000.0 | 122,437,000.0 | 3,122,000.0 | 74,831,000.0 | — |